Clinical Trial

A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-17; most recent amendment 2026-02-26.
Status change: Not Yet Recruiting → Recruiting 2025-11-25
Trial Details
NCT Number NCT07035886
Lead Sponsor Takeda
Conditions Colorectal Cancer
Enrollment 600 participants
Start Date 2025-09-29
Primary Completion 2029-09-01 (estimated)
Study Completion 2031-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-27